Efficacy of Amicar for Children Having Craniofacial Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Amicar (ε-aminocaproic acid) is effective in reducing blood loss in children undergoing craniofacial reconstruction surgery.

The investigators hypothesize that Amicar will decrease intraoperative blood loss and decrease the need for perioperative blood product administration in children undergoing craniofacial surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amicar Pharmacokinetics of Children Having Craniofacial Surgery

NCT00912119

Craniosynostosis

COMPLETED PHASE1

Pharmacokinetics of Aminocaproic Acid in Scoliosis Surgery

NCT01408823

Scoliosis

COMPLETED

Prevention of Post Operative Bone Loss in Children

NCT00655681

Osteoporosis Cerebral Palsy Spina Bifida +2 more

COMPLETED NA

Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor

NCT03328858

Brain Tumors

TERMINATED NA

The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome

NCT07206537

Pediatrics Nephrology

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Craniosynostosis is a condition in which there is premature fusion of one or more of the sutures between the bones of the skull. Premature fusion of sutures in the skull limits the ability of the cranial vault to expand to accommodate the rapidly growing brain in infancy and early childhood and leads to bony deformation. Left uncorrected, craniosynostosis may adversely impact both neurologic and psychosocial development and in some cases, can result in high intracranial pressure and blindness.

Craniofacial (CF) reconstructive surgery is performed in young children with craniosynostosis to improve physical appearance, prevent functional neurologic disturbances, and enhance psychosocial development. Due to the complexities of the surgery as well as the young age and size of the patients, CF reconstruction carries potential life threatening risks and can result in significant morbidity. Reported complications include massive intraoperative hemorrhage, intraoperative cardiac arrest, transfusion-related reactions, venous air embolism, hypotension, coagulopathy, bradycardia, postoperative seizures, surgical site infections, facial swelling with airway compromise, and unplanned postoperative mechanical ventilation. The most severe and most common perioperative issues relate to the rate and extent of blood loss.

Fibrinolysis, which impairs adequate hemostasis, has been shown to occur in children during CF reconstruction. This most certainly contributes to the magnitude of blood loss in these types of operations. Thus, targeting this defect in clot hemostasis with the use of antifibrinolytics is a reasonable therapeutic approach.

Amicar (ε-aminocaproic acid) is a synthetic lysine analog that blocks the lysine binding sites on plasminogen, resulting in antifibrinolytic activity through inhibition of plasmin formation. We have chosen to study Amicar in this clinical context for a number of reasons. First, major hemorrhage continues to be a significant perioperative issue in this cohort. Secondly, Amicar is commonly and safely administered to children undergoing other types of high-risk surgery (i.e., spinal fusion surgery and open heart surgery). In addition, Amicar is inexpensive and easily administered, making it a viable and novel therapeutic option if shown to be effective for this type of surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Craniosynostosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amicar (ε-aminocaproic acid)

Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.

Group Type EXPERIMENTAL

Amicar (ε-aminocaproic acid)

Intervention Type DRUG

normal saline

Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.

Group Type PLACEBO_COMPARATOR

normal saline

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amicar (ε-aminocaproic acid)

Intervention Type DRUG

normal saline

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Amicar 6-aminohexanoic acid epsilon aminocaproic acid normal saline 0.9% placebo placebo control

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any child diagnosed with craniosynostosis in need of surgical repair
* Males and females between the ages of 2 - 36 months (minorities will be included)
* Surgical procedure involving complex craniofacial reconstruction and craniotomy
* Written informed consent from parent/guardian

Exclusion Criteria

* Subjects with known or suspected hypersensitivity reaction to Amicar or history of prior Amicar exposure
* Presence or prior history of a known coagulation disorder or hypercoagulable state
* Preoperative laboratory values that indicate clinically significant hematologic disease (hemoglobin, platelet count, prothrombin time, or partial thromboplastin time outside of normal range)
* Subjects who are on anticoagulant therapy (Coumadin, heparin, aspirin, etc.)
* Subjects with a prior history of a thrombotic event
* History of renal malformation
* Presence of hematuria
* History of abnormal renal function - serum creatinine or blood urea nitrogen (BUN) value greater than 1.5 times the upper limit of the normal range
* Craniofacial reconstruction surgery performed in conjunction with an additional surgical procedure associated with blood loss
* Subjects who have been previously enrolled in this protocol may not be enrolled again

Minimum Eligible Age

2 Months

Maximum Eligible Age

36 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No